abrdn Life Sciences Investors Shares of Beneficial Interest (HQL)

FairStock Score: 53/100 — MIXED

Key Financials

Strengths

• Solid return on equity of 17.6% above cost of capital
• Altman Z-Score of 185.9 confirms minimal bankruptcy risk and strong solvency
• Attractive 11.2% dividend yield providing steady income returns

Concerns

• Weak Piotroski F-Score of 0/9 suggests deteriorating financial quality across multiple dimensions

AI Analysis

abrdn Life Sciences Investors Shares of Beneficial Interest is a micro-cap financial services company valued at $534 million. Revenue stands at $2 million. From a quality standpoint, abrdn shows weak Piotroski F-Score of 0/9 signaling deteriorating fundamentals and Altman Z-Score of 185.9 confirms fortress-level solvency. On valuation, the stock is deeply undervalued on a P/E basis at 6.4x, with offers a 47% margin of safety vs Graham Number of $33. The 11.2% dividend yield adds an income component for patient holders. Our composite FairStock Score of 53/100 reflects mixed fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

The market underappreciates abrdn's consistent 18% ROE at just 6x earnings—a re-rating toward sector peers could unlock 30-50% upside. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the financial services space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer